돈이 보이는 블로그

공모주명 증권사 총배정수량 균등배분수량 청약신청건수 청약신청수량 예상배정수량(균등) 비례배분수량 청약신청수량(비례) 청약율(비례) 리셋버튼 아래의 수치로 작동 여부를 확인하실 수 있습니다. 다음과 같은 값을 입력합니다: 공모주명 (B1): 임의의 텍스트 값 (필수 아님) 증권사 (B2): 1000 총배정수량 (B3): 500 청약신청건수 (B5): 200 청약신청수량 (B6): 300 각 필드에 값을 입력한 후 결과가 제대로 계산되는지 확인합니다: 균등배분수량 (B4): 500 예상배정수량(균등) (B7): 2.50 비례배분수량 (B8): 100 청약신청수량(비례) (B9): 250 청약율(비례) (B10): 150%

이미지 다운로드 및 웹 탐색 도구 웹 검색 검색 초기화 이미지 다운로드 1. 아래 입력창에 웹페이지 URL을 입력하세요. 2. "이미지 로드" 버튼을 클릭하세요. 3. 불러온 이미지 중 다운로드하고 싶은 이미지를 클릭하세요. 4. 이미지가 자동으로 다운로드되지 않으면 마우스 오른쪽 버튼을 클릭하고 "다른 이름으로 저장"을 선택하세요. 5. 자동 다운로드된 이미지는 다운로드 폴더에서 찾을 수 있습니다. 이미지 로드 초기화

   Soaring Korean stocks HLB Pharmaceutical's stock price rise   The main reason for the recent rise in HLB Pharmaceutical's stock price is the expectation that the stock price will rebound and the expectation of a retry, even though it failed to receive FDA approval for its liver cancer drug riboceranib. HLB Pharmaceuticals has applied for a first-line product approval (NDA) from the FDA for the combination of riboceranib and China's Hangseo Pharmaceutical's camrelizumab, and the recent news that Hangseo Pharmaceutical's Chemical Manufacturing Quality Control (CMC) due diligence results showed no particular issues, increasing the possibility of FDA approval. As a result, HLB Pharmaceutical's stock price continues to rise In addition, HLB Pharmaceuticals has achieved the highest half-year sales in its history, and the company's financial position is improving. Sales in the first half of 2023 grew 60% year-on-year to KRW 67.6 billion, driven by the rapi...

     Why is the Stock of Suresofttech in the Korean Market Rising Sharply?       Cooperation with Hyundai Motor Group: Since 2010, Suresoft Tech has maintained a cooperative relationship by providing verification tools and services related to vehicle software (S/W) safety to Hyundai Motor Group. This has positively affected Suresoft Tech's stock price as Hyundai focused on developing and commercializing autonomous vehicle technology. Nuclear Business Orders: Earlier this year, SuresoftTech won W2.5 billion in orders for nuclear power, which is expected to result in a rise in annual sales. With more than 15 years of experience in testing and validating nuclear instrumentation control systems, the company is positioned as a significant partner in the nuclear industry. Software Defined Vehicle (SDV) Growth Beneficiary: According to Research, Suresofttech is emerging as a beneficiary of the Software Defined Vehicle (SDV), a key keyword for CES 2024. The...

     Why is the Stock of KEPCO business in the Korean Market Rising Sharply?   Commercialization of Superconducting Transmission Platform: KEPCO Industrial is indirectly benefiting from the world's first commercialization of superconducting transmission technology developed by KEPCO. The technology is attracting great attention in the global power market because it is more efficient than conventional transmission methods. As a result, KEPCO Industrial's stock price also showed an upward trend. Improving government policies and performance: The rise in the KEPCO industry also reflects expectations from the government's energy-related policies and improved corporate performance. The recently announced increase in second-quarter sales compared to the same period last year had a positive impact. Soaring stocks Domestic stock KEPCO business company information Year of establishment: 1985 Major projects: Electricity meter reading, operation and maintenance of po...

   Why is the Stock of Gwangmoo in the Korean Market Rising Sharply?   Several factors contributed to the rise in Gwangmu's stock price. EPCamtech Acquires Stake: Gwangmu Recent Precision Chemical Materials Through the paid-in capital increase of specialized company EPCamtech, it signed a contract to acquire new shares worth 19.4 billion won and secured a 10% stake to become the second-largest shareholder. EPCamtech is a company that supplies core materials for electric vehicle batteries, and through this acquisition, Gwangmu is expected to expand its business and increase sales. Jecheon Plant Extension and Renovation: Gwangmu plans to complete the expansion and renovation of the Jecheon plant, and to complete the addition of facilities in the first half of the year and operate from the second half. The Jecheon plant is close to major customers of electrolyte additives, so it is expected to increase manufacturing sales in the future. Electrolyte Additives Business: G...

 라메디텍 공모주 청약일정   라메디텍의 공모주 청약 일정과 기업 정보는 다음과 같습니다. 공모주 청약 일정 수요예측 : 5 월  27 일부터  31 일까지 확정 공모가 발표 : 6 월  3 일 일반 청약 : 6 월  5 일부터  7 일까지 환불일 : 6 월  11 일 상장일 : 6 월 중 예정 주간사: 대신증권  라메디텍 공모주 기업정보 설립일 : 2012 년  1 월  25 일 주요 사업 :  의료기기 제조 및 판매  ( 레이저 기기 ),  미용기기 제조 및 판매 사원수 :  약  22 명  (2020 년 기준 ) 대표자 :  최종석 본사 위치 :  서울 금천구 벚꽃로  234,  에이스하이엔드타워 6 차  10 층   라메디텍은 레이저 채혈기와 미용기기 등을 생산하는 전문기업으로 ,  기술성 평가에서  ‘A’  등급을 받으며 기술특례 조건으로 상장하게 됩니다